Tag: antibody-drug conjugates

January 18, 2019

Immunomedics Receives Complete Response Letter From FDA for Sacituzumab Govitecan Biologics License Application

Immunomedics (NASDAQ:IMMU) a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced it has received a Complete Response Letter...
December 6, 2018

Immunomedics Provides Clinical Updates on Breast Cancer Programs With Sacituzumab Govitecan

Immunomedics (NASDAQ:IMMU) a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today presents updated Phase 2 results at the 2018...
August 24, 2018

Immunomedics Announces Fourth Quarter and Fiscal Year 2018 Results and Provides Corporate Update

Immunomedics (NASDAQ:IMMU) a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), reported financial results for the fourth quarter and...
June 13, 2018

Immunomedics Announces Pricing of Public Offering of Common Stock

Immunomedics (NASDAQ:IMMU) a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), announced the pricing of an underwritten public offering...
June 6, 2018

ImmunoGen Announces Proposed Public Offering of Common Stock

ImmunoGen (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that...